Q-omics provides the consensus-scored SPRR2B profile across patient tissues and cancer cell-line models. SPRR2B expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, SPRR2B is differentially expressed in 4, with the highest sampling consensus in LUSC. Additionally, SPRR2B RNA expression shows 9,352 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight READ, LUSC, and ESCA as cancer lineages where SPRR2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPRR2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPRR2B survival associations across molecular data types. SPRR2B RNA expression shows survival associations in the most cancer types (19), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPRR2B RNA expression–survival associations across cancer types. High SPRR2B expression shows unfavorable associations in READ, BLCA, KIRC, ACC, BRCA and SKCM. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for SPRR2B RNA expression.
This table summarizes SPRR2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for SPRR2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPRR2B shows lower tumor expression in BRCA, LUAD and READ and higher tumor expression in LUSC. The LUSC box plot shows higher SPRR2B RNA expression in tumor versus normal tissue (log2 FC = +2.207, t-test p < 0.001).
This table shows molecular features associated with SPRR2B in patient tissues and cancer cell lines. In patient samples, SPRR2B shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, SPRR2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and SKIN.
